Document is current
Any future updates will be listed below
-
Authors
Marchenko, Natalia
Nesbitt, Natasha M.
Alexandrova, Evguenia
Reisz, Julie A.
D’Alessandro, Angelo
Suh, Joonhyuk
Uryasev, Stan
Pennacchia, Lisa
Bahou, Wadie F.
-
Funding
Funding for this research was provided by:
National Cancer Institute (NCI CA284999)
National Cancer Institute (P30CA046934)
Carol Baldwin Breast Cancer Award
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 2 October 2025
First Online: 16 October 2025
Declarations
:
: Not applicable.
: Not applicable.
: WFB is the Founder of Blood Cell Technologies (BCT) which is developing BLVRB small molecular inhibitors for clinical applicability.
